Empagliflozin treatment is also associated with a lower risk of HF, all-cause mortality, and end-stage renal disease in comparison with dipeptidyl peptidase-4 (DPP-4) inhibitors in routine clinical practice in Japan, South Korea, and Taiwan.40 The gene discussed is DPP4; the disease is stage 5 chronic kidney disease.